GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001, n=10) and 100% of patients in remission at Day 8Primary...
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 clinical trial to evaluate proprietary aerosol...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.21 | -2.27027027027 | 9.25 | 9.33 | 8.55 | 70799 | 8.87716799 | CS |
4 | 1.54 | 20.5333333333 | 7.5 | 10.23 | 6.95 | 96952 | 8.55426706 | CS |
12 | 0.94 | 11.6049382716 | 8.1 | 11.09 | 6.72 | 75708 | 8.55934315 | CS |
26 | -3.56 | -28.253968254 | 12.6 | 14 | 6 | 59511 | 8.50452287 | CS |
52 | 1.71 | 23.3287858117 | 7.33 | 14.99 | 6 | 73699 | 9.55792547 | CS |
156 | -7.12 | -44.0594059406 | 16.16 | 21.32 | 5.05 | 72707 | 10.36907118 | CS |
260 | -12.96 | -58.9090909091 | 22 | 30.43 | 5.05 | 81307 | 13.24730832 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales